(Q52010912)

19 April 2018

title

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. (English)

1 reference

19 April 2018

0 references

1 reference

1 reference

Massimo Zuin

1 reference

Pier Maria Battezzati

1 reference

Alfredo Alberti

1 reference

Giuseppe Mazzella

1 reference

author name string

G Fattovich

1

1 reference

19 April 2018

G Giustina

2

1 reference

19 April 2018

S Favarato

3

1 reference

19 April 2018

A Ruol

4

1 reference

19 April 2018

publication date

1 January 1996

1 reference

19 April 2018

published in

Journal of Hepatology

1 reference

19 April 2018

volume

24

1 reference

19 April 2018

page(s)

38-47

1 reference

19 April 2018

issue

1

1 reference

19 April 2018

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Liver failure due to recombinant alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Fatal exacerbation of chronic hepatitis B induced by recombinant alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Psychiatric complications of long-term interferon alfa therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Seizures associated with low-dose alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

UCLA conference. Interferon: immunobiology and clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Suicide associated with alfa-interferon therapy for chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Autoantibodies during alpha-interferon therapy for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Incidence and prevalence rates of diabetes mellitus in Italy from routine data: a methodological assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Clinical toxicity of interferons in cancer patients: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980184-X

7 January 2021

10.1016/S0168-8278(96)80184-X

Identifiers

DOI

1 reference

19 April 2018

PubMed ID

8834023

1 reference

19 April 2018